Assignee
VACCINEX INC
US·42 granted patents·21 pending applications·309 citations·filing 2004–2025
Top patents by PatentIndex Score
63 records- 0197US9828435B2Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequencyVACCINEX INC·Filed 2014·Granted Nov 28, 2017·22 cites·19 claims
- 0296US9243068B2Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastasesVACCINEX INC·Filed 2014·Granted Jan 26, 2016·25 cites·11 claims
- 0396US7919594B2Human anti-CD100 antibodiesVACCINEX INC·Filed 2008·Granted Apr 5, 2011·55 cites·36 claims
- 0495US9249227B2Use of semaphorin-4D binding molecules for treating neurodegenerative disordersVACCINEX INC·Filed 2015·Granted Feb 2, 2016·18 cites·23 claims
- 0594US9512224B2Use of semaphorin-4D binding molecules for treatment of atherosclerosisVACCINEX INC·Filed 2014·Granted Dec 6, 2016·11 cites·22 claims
- 0694US9090709B2Anti-SEMA4D antibodies and epitopesVACCINEX INC·Filed 2013·Granted Jul 28, 2015·18 cites·7 claims
- 0793US7919095B2Anti-IL-6 monoclonal antibodiesVACCINEX INC·Filed 2007·Granted Apr 5, 2011·27 cites·9 claims
- 0892US12006365B2Human anti-semaphorin 4D antibodyVACCINEX INC·Filed 2022·Granted Jun 11, 2024·1 cites·27 claims
- 0992US9890213B2Methods for the treatment of B cell-mediated inflammatory diseasesVACCINEX INC·Filed 2013·Granted Feb 13, 2018·10 cites·15 claims
- 1092US9605055B2Anti-CD100 antibodies and methods of using the sameVACCINEX INC·Filed 2013·Granted Mar 28, 2017·14 cites·11 claims
- 1192US9598495B2Use of semaphorin-4D binding molecules for treating neurodegenerative disordersVACCINEX INC·Filed 2014·Granted Mar 21, 2017·16 cites·11 claims
- 1292US9371352B2Modified glycolipids and methods of making and using the sameVACCINEX INC·Filed 2013·Granted Jun 21, 2016·10 cites·29 claims
- 1391US11859000B2Anti-CCR8 antibodies and uses thereofVACCINEX INC·Filed 2021·Granted Jan 2, 2024·3 cites·20 claims
- 1491US9676840B2Anti-CD100 neutralizing antibodies and methods of using the sameVACCINEX INC·Filed 2013·Granted Jun 13, 2017·11 cites·28 claims
- 1590US10111950B2Modified glycolipids and methods of making and using the sameVACCINEX INC·Filed 2016·Granted Oct 30, 2018·5 cites·9 claims
- 1690US8790652B2Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesisVACCINEX INC·Filed 2012·Granted Jul 29, 2014·20 cites·22 claims
- 1790US2025032609A1Use of semaphorin-4d antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasisVACCINEX INC·Filed 2024·Application pending·0 cites
- 1889US11078295B2Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastasesVACCINEX INC·Filed 2019·Granted Aug 3, 2021·2 cites·20 claims
- 1989US9708601B2Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virusVACCINEX INC·Filed 2013·Granted Jul 18, 2017·7 cites·4 claims
- 2088US9790271B2Methods for increasing immunoglobulin A levelsVACCINEX INC·Filed 2014·Granted Oct 17, 2017·10 cites·30 claims
- 2188US9701958B2Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunitsVACCINEX INC·Filed 2015·Granted Jul 11, 2017·4 cites·13 claims
- 2287US10577427B2Integral membrane protein display on poxvirus extracellular enveloped virionsVACCINEX INC·Filed 2017·Granted Mar 3, 2020·3 cites·12 claims
- 2385US11597765B2Use of semaphorin-4D binding molecules for the treatment of Rett syndromeVACCINEX INC·Filed 2021·Granted Mar 7, 2023·2 cites·16 claims
- 2485US11427634B2Human anti-semaphorin 4D antibodyVACCINEX INC·Filed 2018·Granted Aug 30, 2022·4 cites·50 claims
- 2585US10550199B2Integral membrane protein display on poxvirus extracellular enveloped virionsVACCINEX INC·Filed 2019·Granted Feb 4, 2020·2 cites·24 claims
- 2685US10301393B2Methods of treating multiple sclerosis using anti-CD20 antibodiesVACCINEX INC·Filed 2016·Granted May 28, 2019·4 cites·6 claims
- 2784US10385136B2Use of semaphorin-4D binding molecules for treating neurodegenerative disordersVACCINEX INC·Filed 2017·Granted Aug 20, 2019·3 cites·15 claims
- 2882US12496342B2Anti-CCR8 antibodies and uses thereofVACCINEX INC·Filed 2023·Granted Dec 16, 2025·0 cites·33 claims
- 2982US10800853B2Use of semaphorin-4D binding molecules for treating neurodegenerative disordersVACCINEX INC·Filed 2019·Granted Oct 13, 2020·1 cites·15 claims
- 3082US2026091108A1Anti-ccr8 antibodies and uses thereofVACCINEX INC·Filed 2025·Application pending·0 cites
- 3181US12006364B2Anti-CD100 antibodies and methods for using the sameVACCINEX INC·Filed 2022·Granted Jun 11, 2024·0 cites·13 claims
- 3280US11534488B2Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeabilityVACCINEX INC·Filed 2019·Granted Dec 27, 2022·1 cites·9 claims
- 3380US2024309091A1Human anti-semaphorin 4d antibodyVACCINEX INC·Filed 2024·Application pending·0 cites
- 3479US12070500B2Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasisVACCINEX INC·Filed 2021·Granted Aug 27, 2024·0 cites·13 claims
- 3571US10526414B2Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasesVACCINEX INC·Filed 2017·Granted Jan 7, 2020·0 cites·6 claims
- 3670US11274149B2Anti-CD100 antibodies and methods for using the sameVACCINEX INC·Filed 2017·Granted Mar 15, 2022·0 cites·13 claims
- 3769US10870707B2Integral membrane protein display on poxvirus extracellular enveloped virionsVACCINEX INC·Filed 2019·Granted Dec 22, 2020·0 cites·15 claims
- 3868US11981730B2Anti-CXCL13 antibodies and methods of using the sameVACCINEX INC·Filed 2020·Granted May 14, 2024·0 cites·12 claims
- 3966US2025052757A1Use of PD-L1 Low Expression Status to Select Subjects for Cancer ImmunotherapyVACCINEX INC·Filed 2024·Application pending·0 cites
- 4063US10640765B2Methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cellsVACCINEX INC·Filed 2019·Granted May 5, 2020·0 cites·30 claims
- 4162US10829550B2Polynucleotides encoding anti-CXCL13 antibodiesVACCINEX INC·Filed 2018·Granted Nov 10, 2020·0 cites·14 claims
- 4261US2023101618A1Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disordersVACCINEX INC·Filed 2022·Application pending·0 cites
- 4360US2023331863A1Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's diseaseVACCINEX INC·Filed 2023·Application pending·0 cites
- 4459US10662422B2Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunitVACCINEX INC·Filed 2017·Granted May 26, 2020·0 cites·4 claims
- 4559US2024093177A1Methods to select antibodies specific to complex membrane antigensVACCINEX INC·Filed 2023·Application pending·0 cites
- 4659US2020299683A1Methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cellsVACCINEX INC·Filed 2020·Application pending·0 cites
- 4759US2005158323A1Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cellsVACCINEX INC·Filed 2004·Application pending·0 cites
- 4857US2019169606A1Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cellsVACCINEX INC·Filed 2017·Application pending·0 cites
- 4956US2005042218A1MHC class I - peptide-antibody conjugates with modified beta2-microglobulinVACCINEX INC·Filed 2004·Application pending·0 cites
- 5055US2004210037A1Targeted MHC class I alpha3 vaccine delivery systemsVACCINEX INC·Filed 2004·Application pending·0 cites
Showing the top 50 of 63 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →